A detailed history of Lazard Asset Management LLC transactions in Argenx Se stock. As of the latest transaction made, Lazard Asset Management LLC holds 5,953 shares of ARGX stock, worth $3.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,953
Previous 398 1395.73%
Holding current value
$3.72 Million
Previous $171,000 1787.72%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $2.41 Million - $3.07 Million
5,555 Added 1395.73%
5,953 $3.23 Million
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $193,669 - $245,643
-544 Reduced 57.75%
398 $171,000
Q1 2024

May 14, 2024

SELL
$356.95 - $413.29 $854,538 - $989,416
-2,394 Reduced 71.76%
942 $370,000
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $391,102 - $583,935
-1,154 Reduced 25.7%
3,336 $1.27 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $1.59 Million - $2.36 Million
4,310 Added 2394.44%
4,490 $2.21 Million
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $453,215 - $547,349
-1,356 Reduced 88.28%
180 $67,000
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $460,574 - $531,096
1,342 Added 691.75%
1,536 $542,000
Q4 2021

Feb 09, 2022

SELL
$272.01 - $353.03 $50,321 - $65,310
-185 Reduced 48.81%
194 $67,000
Q1 2021

May 14, 2021

BUY
$268.3 - $380.31 $1,341 - $1,901
5 Added 1.34%
379 $104,000
Q3 2020

Nov 13, 2020

BUY
$215.51 - $272.51 $80,600 - $101,918
374 New
374 $98,000
Q4 2019

Feb 13, 2020

SELL
$106.59 - $164.21 $1.16 Million - $1.78 Million
-10,859 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$113.31 - $150.51 $22,662 - $30,102
-200 Reduced 1.81%
10,859 $1.24 Million
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $23,000 - $28,316
200 Added 1.84%
11,059 $1.57 Million
Q4 2018

Feb 13, 2019

BUY
$63.81 - $109.82 $692,912 - $1.19 Million
10,859 New
10,859 $1.04 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.